Mind the gap: Bridging the divide between digital health potential and realityShould digital health innovators be doing more to ensure healthcare professionals have the knowledge they need to embed Share XMind the gap: Bridging the divide between digital health potential and realityhttps://pharmaphorum.com/views-analysis-digital/mind-the-gap-bridging-the-divide-between-digital-health-potential-and-reality/
A year of building patient centric foundationsIt’s been a year of putting patient centricity theory into practice, as companies and industry organisations alike have Share XA year of building patient centric foundationshttps://pharmaphorum.com/views-analysis-patients/2019-in-review-a-year-of-building-patient-centric-foundations/
Future proofing the UK’s research ecosystem in the face of global changeThe UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits Share XFuture proofing the UK’s research ecosystem in the face of global changehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-proofing-the-uks-research-ecosystem-in-the-face-of-global-change/
Harnessing the digital transformation of the drug development pathwayWe have the evidence base to support the digital transformation of clinical trials – what we need now Share XHarnessing the digital transformation of the drug development pathwayhttps://pharmaphorum.com/views-analysis-digital/harnessing-the-digital-transformation-of-the-drug-development-pathway/
ABPI’s blueprint to build a pharma powerhouse in uncertain political timesThe UK is in the grips of election fever, but whoever takes the reins on 13 December will Share XABPI’s blueprint to build a pharma powerhouse in uncertain political timeshttps://pharmaphorum.com/r-d/views-analysis-r-d/abpis-blueprint-to-build-a-pharma-powerhouse-in-uncertain-pollical-times/
How to address racial disparities in clinical trial dataIn the US, fewer than three per cent of eligible patients participate in clinical trials – a figure Share XHow to address racial disparities in clinical trial datahttps://pharmaphorum.com/views-analysis-patients/utilising-technology-racial-disparities-clinical-trial-data/
Joined up thinking and innovation will boost drug development in rare diseasesFresh thinking and greater collaboration at the European level could accelerate the much-needed development of treatments and cures Share XJoined up thinking and innovation will boost drug development in rare diseaseshttps://pharmaphorum.com/views-analysis-patients/innovation-drug-development-rare-diseases/
A blueprint for building a patient-centric pharma companyWhile the industry appears united in its commitment to patient centricity, the practicalities of embedding the ethos into Share XA blueprint for building a patient-centric pharma companyhttps://pharmaphorum.com/views-analysis-patients/whitepaper-provides-a-blueprint-to-building-a-patient-centricity-company/
Measuring value to ensure access in divisive timesGlobally, balancing rising healthcare costs with the drive for innovation is a political hot potato – is a Share XMeasuring value to ensure access in divisive timeshttps://pharmaphorum.com/views-analysis-market-access/measuring-value-to-ensure-access-in-divisive-times/
